Imiquimod
Active ingredient: Imiquimod
In short: Imiquimod cream, 3.75% is indicated for the topical treatment of clinically typical, visible or palpable actinic keratoses (AK) of the face or balding scalp in immunocompetent adults. Imiquimod cream, 3.75% is indicated for the topical treatment of external genital and perianal warts (EGW) in immuno
What is Imiquimod used for?
Imiquimod cream, 3.75% is indicated for the topical treatment of clinically typical, visible or palpable actinic keratoses (AK) of the face or balding scalp in immunocompetent adults.
Imiquimod cream, 3.75% is indicated for the topical treatment of external genital and perianal warts (EGW) in immunocompetent patients 12 years of age and older.
Imiquimod dosage
Imiquimod cream is for topical use only. Imiquimod cream is not for oral, ophthalmic, intra-anal or intravaginal use. Instruct patients on proper application technique.
Wash hands before and after applying imiquimod cream.
Prime the imiquimod cream pump bottle before first use by repeatedly depressing the actuator until the cream is dispensed. It is not necessary to repeat this priming process during treatment.
If a imiquimod cream dose is missed, apply the next dose at the regularly scheduled time.
Avoid contact with the eyes, lips, nostrils, or inside the anus and vagina.
Prescribe no more than 2 boxes (56 packets) or two 7.5 g bottle pumps of imiquimod cream for the entire treatment course for AK or EGW.
Discard partially used packets and do not reuse. Discard pump bottles after completion of a full treatment course.
Use imiquimod cream, 3.75% for the treatment of AK. Apply a thin layer of imiquimod cream once daily before bedtime to the area with AK (either entire face or balding scalp) for two 2-week treatment cycles separated by a 2-week no-treatment period. Rub in until the cream is no longer visible. Apply up to 0.5 grams (two packets or two full actuations of the pump) of imiquimod cream at each application. Leave imiquimod cream on the skin for approximately 8 hours and then remove with mild soap and water.
For local skin reactions, a dosage interruption of several days may be taken if required based on the patient's discomfort or severity of the local skin reaction
.Do not extend either 2-week treatment cycle due to missed doses or rest periods. Assess response to treatment after resolution of local skin reactions.
A transient increase in lesion counts may be observed during treatment; however, continue dosing as prescribed. Continue treatment for the full treatment course even if all AK appear to be gone.
Use imiquimod cream, 3.75% for the treatment of EGW. Apply a thin layer of imiquimod cream once daily before bedtime to EGW until total clearance or for up to 8 weeks. To treat the wart area, use up to 0.25 grams (one packet or one full actuation of the pump) at each application. Leave imiquimod cream on the skin for approximately 8 hours and then remove with mild soap and water.
For local skin reactions, a dosage interruption of several days may be taken if required by the patient's discomfort or severity of the local skin reaction; resume treatment once the reaction subsides
.Non-occlusive dressings such as cotton gauze or cotton underwear may be used in the management of skin reactions.
Inform uncircumcised patients treating warts under the foreskin to retract the foreskin and clean the area daily.
Imiquimod cream may weaken condoms and vaginal diaphragms, therefore, concurrent use is not recommended.
How to take Imiquimod — instructions & advice from the label
Advise the patient to read the FDA-approved patient labeling (Patient Information).
Important Administration Instructions
Inform all patients of the following
:
• Imiquimod cream is for topical use only and avoid contact with the eyes, lips, nostrils, or inside the anus and vagina. Instruct patients to rinse their mouth or eyes with water right away if contact with these areas occur.
• Wash their hands before and after applying imiquimod cream.
• If a imiquimod cream dose is missed, apply the next dose at the regularly scheduled time.
• Discard and do not reuse partially used packets.
• Discard pump bottles after completion of a full treatment course.
Inform patients with EGW of the following
:
• Uncircumcised patients treating warts under the foreskin should retract the foreskin and clean the area daily.
• Imiquimod cream may weaken condoms and vaginal diaphragms; therefore, concurrent use is not recommended.
• Avoid sexual (genital, anal, oral) contact while imiquimod cream is on the skin.
• Do not bandage or otherwise occlude the treatment area. …
Warnings & precautions
Do not take this medicine if: None.
Local skin reactions including skin weeping or erosion have been reported with use of imiquimod cream and can occur after a few applications
. Concomitant use of imiquimod cream and any other imiquimod products, in the same treatment area, may increase the risk for and severity of local skin reactions.
Imiquimod cream has the potential to exacerbate inflammatory conditions of the skin, including chronic graft versus host disease.
Severe local inflammatory reactions of the female external genitalia can lead to severe vulvar swelling and to urinary retention.
Avoid sexual (genital, anal, oral) contact while imiquimod cream is on the skin.
To reduce the risk of local skin reactions and manage local skin reactions that occur with imiquimod cream treatment:
Avoid concomitant use of imiquimod cream with any other imiquimod product in the same treatment area.
Avoid application of imiquimod cream to skin that is not intact (i.e., any area with an abrasion, cut, burn, rash, infection, or other condition that has altered skin integrity).
An interruption of dosing may be required for local skin reactions
. Interrupt dosing or discontinue imiquimod cream for severe vulvar swelling
.
If severe local skin reactions occur, instruct patients to remove imiquimod cream by washing the treatment area with mild soap and water.
Flu-like signs and symptoms have been reported with use of imiquimod cream andmay accompany, or even precede, local skin reactions
.
Signs and symptoms may include fatigue, nausea, fever, myalgias, arthralgias, malaise and chills. Concomitant use of imiquimod cream and any other imiquimod products may increase the risk for and severity of systemic reactions.
Lymphadenopathy occurred in 2% of subjects with AK treated with imiquimod cream, 3.75% and in no patients in the vehicle arm
. …
Imiquimod side effects
The following clinically significant adverse reactions are described elsewhere in the labeling:
• Local Skin Reactions
• Systemic Reactions
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
Actinic Keratosis
The data described below reflect exposure to imiquimod cream or vehicle in 479 subjects with AK enrolled in two double-blind, vehicle-controlled trials (Studies AK1 and AK2) . Subjects applied up to two packets of imiquimod cream, 3.75%, or vehicle once daily, to the skin of the affected area (either entire face or balding scalp) for two 2-week treatment cycles separated by a 2-week no treatment period. Selected adverse reactions are listed in Table 1. …
About this medicine
Imiquimod Cream, 3.75% is for topical administration. Each gram contains 37.5 mg of imiquimod in an off-white oil-in-water vanishing cream base consisting of benzyl alcohol, cetyl alcohol, glycerin, isostearic acid, methylparaben, polysorbate 60, propylparaben, purified water, sorbitan monostearate, stearyl alcohol, white petrolatum, and xanthan gum.
Chemically, imiquimod is 1-(2-methylpropyl)-1
H-imidazol[4,5-c]quinolin-4-amine. Imiquimod has a molecular formula of
C
14H
16N
4and a molecular weight of 240.3. Its structural formula is:
How it works: The mechanism of action of imiquimod cream in treating AK and EGW lesions is unknown. The pharmacodynamics of imiquimod cream are unknown. Imiquimod is a Toll-like receptor 7 agonist that activates immune cells.
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 5c19b687-fd29-b22e-e063-6294a90ad67b. Read the full official label on DailyMed.